Evidence map›Paper›PMID 41009525›Full record

ArticleInternational journal of molecular sciences2025

Xuan Zhang, Qiyao Xiao, Haoran Chen, Shaoming Yang, Qingli Li, Lihua Peng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xuan ZhangCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Qiyao XiaoCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Haoran ChenCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Shaoming YangLongquan Industrial Innovation Research Institute, Zhejiang University, Longquan 323700, China.
Qingli LiLongquan Industrial Innovation Research Institute, Zhejiang University, Longquan 323700, China.
Lihua PengCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.ORCID 0000-0001-9763-383X

Funding

Longquan Innovation Project of Longquan Institute of Innovation Grant No. ZDLQ 2022014National Key Research and Development Program 2022YFC3501904Zhejiang province commonweal projects LGF22H280001Zhejiang University, the National Natural Science Foundation of China 82374043, U23A20505
6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) accounts for over 80% of lung cancer cases and remains challenging to treat due to high recurrence and mortality rates. While cisplatin (CDDP) is a first-line chemotherapy for NSCLC, its clinical utility is limited by toxicity, drug resistance, and inadequate tumor suppression. Plant-derived extracts have shown promise as complementary therapies, offering potential benefits including enhanced efficacy and reduced treatment side effects. The aqueous extract of

Indexed as

ActinidiaAntineoplastic Agents, PhytogenicCarcinoma, Non-Small-Cell LungLung NeoplasmsPlant ExtractsPlant RootsTOR Serine-Threonine KinasesTransforming Growth Factor betaA549 CellsAnimalsApoptosisCell Line, TumorCell ProliferationHumansMiceSignal TransductionAntineoplastic Agents, PhytogenicMTOR protein, humanPlant ExtractsTOR Serine-Threonine KinasesTransforming Growth Factor betaActinidia eriantha Benth. rootextractnon-small cell lung cancerTGF-β/FOXO/mTOR pathway

Identifiers

PMID41009525
PMCPMC12469755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.